A super-resolution microscopy technique offers an unparalleled glimpse into how monoclonal antibodies bind to their targets ...

Navrogen, Inc. has announced groundbreaking advancements in monoclonal antibody (mAb) and antibody-drug conjugate (ADC) ...

I-Mab Adr ( ($IMAB) ) has released its Q4 earnings. Here is a breakdown of the information I-Mab Adr presented to its investors. I-Mab is a ...

Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) ...

In a recent article published in Nature Cancer, a multi-institutional research team led by The University of Osaka describes ...

In the assessment of 12-month price targets, analysts unveil insights for Y-mAbs Therapeutics, presenting an average target of $14.2, a high estimate of $22.00, and a low estimate of $7.00. This ...

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

Experts reported that water quality has improved compared to last year, with better oxygen levels, less chlorophyll, and ...

Shanghai Henlius Biotech announced that the FDA has granted Orphan Drug Designation for HLX22, an anti-HER2 monoclonal ...

I-Mab (NASDAQ:IMAB) ADRs traded ~11% higher in the premarket after the biotech indicated a faster-than-expected advancement in its Phase 1b trial for its experimental gastric cancer therapy ...

I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in Rockville, ...

I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer.